Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Target Oncol. 2009 Dec;4(4):253-4. doi: 10.1007/s11523-009-0130-0. Epub 2009 Nov 13.

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Author information

  • 1Department of Medical Oncology and Gastroenterology, Beaujon University Hospital, Clichy, France. eric.raymond@bjn.aphp.fr

Abstract

Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.

PMID:
19911111
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk